NTRK Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib). Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial Pyramid will use Tempus' TIME Trial Network to identify and enroll patients eligible for a Phase I/II trial of its TRK inhibitor, PBI-200. Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future. FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors. Bayer, NeoGenomics Launch Free NTRK Fusion Testing Program The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer. Jan 2, 2020 Japanese Regulator Approves Foundation Medicine CDx for Roche's Rozlytrek in Lung Cancer Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Aug 16, 2019 Foundation Medicine to Seek FDA Approval for FoundationOne as CDx to Genentech's Rozlytrek Jun 27, 2019 Japanese Regulator Approves Foundation Medicine CDx Assay for Roche's Rozlytrek May 30, 2019 Caris Life Sciences Plans Integrated Molecular Testing, Trial Matching Service With New Acquisition Premium May 16, 2019 Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors Premium Apr 2, 2019 Bayer, Loxo Next-Generation TRK Inhibitor Shows Promising Activity in AACR Study Premium Jan 8, 2019 Circulogene Broadens Push Into Companion Diagnostics with NTRK Fusion Assay Premium Nov 27, 2018 Loxo's Pan-Cancer Drug Garners FDA Approval for Patients With NTRK Fusions Oct 31, 2018 Lung Cancer Panel From PlexBio Receives CE Mark Oct 24, 2018 Almac Diagnostic Services to Build Pan-Cancer NGS Companion Test for TP Therapeutics Breaking News Canadian Healthcare Providers, Policymakers Value Different Aspects of Clinical Genomic Sequencing New Products Posted to GenomeWeb: Oxford Nanopore, Bio-Rad, NanoString, More People in the News at OraSure, Element Biosciences, Micronoma, More Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit In Brief This Week: SQI Diagnostics, T2 Biosystems, Enhanc3D, QuidelOrtho, More Illumina, Precision Health Research Singapore Partner for 100K Genomes Population Study The Scan Blend of Omicron With Delta The Associated Press reports that currently circulating Omicron variants have some features previously seen in the Delta variant. Limited Contrast The New York Times reports that there is a shortage of a contrast agent used for some medical scans. Pig Improvement Farmers in China are using genetics to improve their hog herds, according to Reuters. Science Papers Present Way to Molecularly Classify Prostate Cancer, Saliva-Based SARS-CoV-2 Test, More In Science this week: approach to molecularly classify prostate tumors, saliva-based test for SARS-CoV-2, and more.